Sabby Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Sabby Management’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Hold	–	-$708	–	276
2014 Q3	–	Hold	–	–	–	169
2014 Q2	–	Hold	–	–	–	126

Other funds holding TNXP

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's TNXP Position: Q2 2024 in Review

Sabby Management sold out of Tonix Pharmaceuticals (TNXP) in Q2 2024, closing a stake of 1,530 shares — an estimated $911K sold.

Sabby Management first reported a position in TNXP in Q3 2023 and held it in 3 quarters. The position peaked at $1.25M in Q4 2023. 13 funds tracked by Wall St. Rank hold TNXP as of Q2 2024.

Sabby Management reported no remaining Tonix Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Sabby Management sold 1,530 Tonix Pharmaceuticals shares in Q2 2024, an estimated $911K.
Sabby Management first reported a position in Tonix Pharmaceuticals in Q3 2023 and held it in 3 quarters.
Sabby Management's Tonix Pharmaceuticals position peaked at $1.25M in Q4 2023.
13 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2024.

Based on Sabby Management's 13F filing for Q2 2024, filed 14 Aug 2024.